Supplementary Figure 4 from <i>Ex Vivo</i> Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies

crossref(2024)

Cited 0|Views12
No score
Abstract

Ratio of CD8+ to CD4+ T cells does not appear to affect sensitivity to SAR442257

More
Translated text
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined